Market cap
$102 Mln
Revenue (TTM)
$82 Mln
P/E Ratio
--
P/B Ratio
0.3
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | 303,703,603.70 | 204.75 | -17.84 | 2.74 |
| EBIT | 260.29 | 167,719.04 | 13.79 | -197.21 | -203.44 |
| Net Profit | 264.39 | 169,752.01 | 15.99 | -196.41 | -201.86 |
| EPS | 264.39 | 163,230.17 | 21.35 | -183.97 | -31.56 |
| Book Value | -- | -- | -21.33 | -11.82 | -8.76 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Dec-22 | Dec-21 | Dec-20 |
| EBIT-Margin
| -158.28 | -96.21 | -63.71 | -338.75 | -72.37 |
| Net Margin
| -155.17 | -93.54 | -61.01 | -335.58 | -68.90 |
| Return on equity
| -29.84 | -13.79 | -25.03 | -41.77 | -22.72 |
| Return on Capital
| -27.81 | -13.11 | -23.65 | -39.03 | -20.75 |
| Return on Assets
| -25.98 | -12.32 | -21.89 | -36.57 | -19.48 |
| Debt to Equity (x)
| -- | -- | 0.05 | 0.06 | 0.08 |
Profitability
ROCE
-23.65
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Jounce Therapeutics (JNCE)
|
-23.65
|
-39.03
|
-20.75
|
38.06
|
-20.18
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-25.03
--
Profit after tax / Average Net worth * 100
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Jounce Therapeutics (JNCE)
|
-25.03
|
-41.77
|
-22.72
|
40.77
|
-20.19
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROA
-21.89
--
Profit after tax / Average Total assets * 100
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Jounce Therapeutics (JNCE)
|
-21.89
|
-36.57
|
-19.48
|
27.04
|
-10.71
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Margin
-63.71
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Jounce Therapeutics (JNCE)
|
-63.71
|
-338.75
|
-72.37
|
35.72
|
-41.92
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Margin
-61.01
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Jounce Therapeutics (JNCE)
|
-61.01
|
-335.58
|
-68.90
|
37.40
|
-39.59
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
2.05
--
Year on year growth in net sales
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Jounce Therapeutics (JNCE)
|
2.05
|
-0.57
|
-0.58
|
1.27
|
-0.09
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Growth
42.63
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Jounce Therapeutics (JNCE)
|
42.63
|
-101.82
|
-185.42
|
293.24
|
-66.59
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Profit Growth
43.97
--
Year on year growth in profit after tax
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Jounce Therapeutics (JNCE)
|
43.97
|
-107.27
|
-177.16
|
307.54
|
-66.51
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EPS Growth
0.46
--
Year on year growth in earnings per share
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Jounce Therapeutics (JNCE)
|
0.46
|
-0.45
|
-1.75
|
3.01
|
-0.51
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.05
--
Total debt / Net worth
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Jounce Therapeutics (JNCE)
|
0.05
|
0.06
|
0.08
|
0.11
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.02
--
(Short term borrowings / Net worth)
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Jounce Therapeutics (JNCE)
|
0.02
|
0.02
|
0.02
|
0.02
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
8.37
--
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Jounce Therapeutics (JNCE)
|
8.37
|
10.10
|
10.94
|
12.06
|
2.93
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Quick Ratio
--
--
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Jounce Therapeutics (JNCE)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Interest Coverage
-35.83
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Jounce Therapeutics (JNCE)
|
-35.83
|
-30.09
|
-9.62
|
6.68
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
--
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Jounce Therapeutics (JNCE)
|
--
|
0.37
|
0.16
|
0.47
|
0.63
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Asset Turnover
0.35
--
Sales / Average Total Assets
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Jounce Therapeutics (JNCE)
|
0.35
|
0.11
|
0.28
|
0.70
|
0.26
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Receivable days
0.45
--
Average Debtors / Sales * 365
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Jounce Therapeutics (JNCE)
|
0.45
|
1.36
|
2.34
|
1.38
|
50.75
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Jounce Therapeutics (JNCE)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Jounce Therapeutics (JNCE)
|
--
|
--
|
--
|
40.45
|
35.86
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Jounce Therapeutics (JNCE)
|
--
|
--
|
--
|
--
|
14.89
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
-1.13
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Jounce Therapeutics (JNCE)
|
-1.13
|
-4.59
|
-5.59
|
5.22
|
-4.06
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
0.32
--
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Jounce Therapeutics (JNCE)
|
0.32
|
1.87
|
1.16
|
1.70
|
1.07
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
2.43
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Jounce Therapeutics (JNCE)
|
2.43
|
92.33
|
-1.33
|
2.61
|
3.34
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|